Shire Reports Positive Data For Angiodema Drug
May 18 2017 - 7:43AM
Dow Jones News
By Rory Gallivan
LONDON-- Drug company Shire PLC (SHP.LN) Thursday said Phase 3
testing of its Lanadelumab treatment showed a significant reduction
in attacks of hereditary angiodema, a rare genetic condition.
Shire will now use the data for its application for approval in
the U.S., which it expects to file towards the end of this year or
early in 2018.
Shares at 1107 GMT, up 173 pence, or 3.7%, at 4904 pence valuing
the company at GBP44.7 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
May 18, 2017 07:28 ET (11:28 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Shire (LSE:SHP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Shire (LSE:SHP)
Historical Stock Chart
From Sep 2023 to Sep 2024